Skip to main content
. 2020 May 12;11:888. doi: 10.3389/fimmu.2020.00888

Table 3.

Selected clinical trials of CAR T cells in multiple myeloma.

Setting Target Product Costimul. domain Generation Vector Population infused Response Durable remission rate CRS (gr.3/4) NTX (gr.3/4) Institute/Company Clinical trial References
MM BCMA BCMA.CAR CD28 Second (2nd) Retroviral 16, R/R MM ORR 81%
≥VGPR 63%
Unknown 38%§ 6%¬ NIH NCT02215967
Phase I
(188)
CART-BCMA 4-1BB Second (2nd) Lentiviral 25, R/R MM ORR 48% Median DOR
≈ 4 mo
32%¥ 12%* UPenn/Novartis NCT02546167
Single-center, phase I
(189)
bb2121 4-1BB Second (2nd) Lentiviral 33, R/R MM ORR 85%
CR 45%
Median DOR 10.9 mo 6%§ 3%± NIH/Bluebird Bio, Celgene NCT02658929 Multicenter phase I (190)
LCAR-B38M None First (1st) Lentiviral 57, R/R MM ORR 88%
CR 68%
Median DOR 14 mo 7%§ 2%± Nanjing Legend Biotech LEGEND-2
NCT03090659
Multicenter phase I/II
(193)
k-Ig LC κ. CAR CD28 Second (2nd) Retroviral 7, R/R MM ≥PR 57% Unknown 0%* 0%* BCM CHARKALL
NCT00881920
Phase I
(102)
NKG2DL CM-CS1 T CD3ζ plus DAP10 Second (2nd) Retroviral 5, R/R MM DFCI/Celyad NCT02203825
in vitro
Phase I
(199)
¥

, Penn/CHOP grading scale;

§

, NCI 2014 consensus grading scale modified by Lee DW et al. (45);

*

, CTCAE v4.0;

¬

, CTCAE v4.02;

±

, CTCAE v4.03.

MM, multiple myeloma; R/R., relapse/refractory; ORR, overall response rate; CR, complete remission; PR, partial response; VGPR, very good partial response; SD, stable disease; wk, weeks; EFS, event-free survival; DOR, duration of response; PFS, progression-free survival; CRS, cytokine release syndrome; NTX, neurotoxicity; UPenn, University of Pennsylvania Hospital; DFCI, Dana-Faber Cancer Institute; NIH, National Institutes of Health; BCM, Baylor College of Medicine.